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CHILDHOOD VACCINATIONS AND AUTISM: DOES THE
NATIONAL CHILDHOOD VACCINE INJURY ACT LEAVE PAR-
ENTS OF CHILDREN WITH AUTISM OUT IN THE COLD
WITH NOWHERE TO GO?
AJ. was born on May 15, 1994, a healthy baby boy.1 Between
May 1994 and December 1995, AJ. was administered standard child-
hood vaccines. When he was eighteen months old, AJ.'s development
began to regress. He began to lose language and motor skills, and
became withdrawn and non-interactive. In May 2001, seven years from
the date of administration of his first vaccine, AJ. was diagnosed with
disintegrative autism resulting from mercury toxicity. The mercury
poisoning allegedly resulted from exposure to cumulative doses of thi-
merosal, a mercury-containing preservative used in vaccines previ-
ously administered to AJ.2 In May 2002, approximately six and one
half years after the first manifestation of his symptoms, AJ.'s parents
initiated a civil action to recover for their son's vaccine-related
3
The current legislation governing such a claim is the National
Childhood Vaccine Injury Act4 ("Vaccine Act"). This comment
explores the interaction of various factors which will ultimately dictate
the possible remedies available to AJ.'s parents and to the parents of
other autistic children across the nation. Namely, the implications of
the Vaccine Act 5 are explored, including the interplay between the
potential causal relationship between childhood vaccines and autism,
the statute of limitations of the Vaccine Act, the development and
import of the Omnibus Autism Proceeding and its effect on potential
remedies available to parents of autistic children, and the constitution-
ality of the Vaccine Act's provision regarding limitations of claims.
Although, when it was enacted in 1986, the Vaccine Act seemed to ade-
quately redress petitioners' claims of vaccine-related injury, the rela-
tively recent and marked increase in the prevalence of autism,
potentially the consequence of childhood vaccinations, was not fore-
seen by the legislature, and, if such a causal association is determined,
1. Cheskiewicz v. Aventis Pasteur, Inc., 2004 PA Super 40, 1 3, 843 A.2d 1258,
1261.
2. Id. at 91 3, 843 A.2d at 1261.
3. Id. at S 4, 843 A.2d at 1261.
4. 42 U.S.C. §§ 300aa-1-34 (2000).
5. Id.
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it cannot be adequately redressed under the Vaccine Act's current stat-
utory scheme.
AUTISM AND THE CAUSAL ASSOCIATION WITH CERTAIN
CHILDHOOD VACCINATIONS
In order to fully appreciate the significance of the remedy limita-
tion created by the Vaccine Act, it is first essential to understand cer-
tain underlying conditions and concepts, including autism, childhood
vaccination, and thimerosal, which interact to fuel ongoing medical
and legal debate regarding the appropriateness and fairness of the Vac-
cine Act.
Autism' is a complex biological disorder that generally lasts
throughout a person's life.7 It is considered a developmental disability
because symptoms first manifest in the developmental period before
age 3 and because it adversely affects many aspects of a person's
growth and development.8 In the majority of cases, autism causes
problems with a person's communication (both verbal and nonverbal),
social interactions (both physical and verbal), and routines or repeti-
tive behaviors, such as repeating words or actions over and over, and
following routines or schedules for his or her actions.9 These charac-
teristic symptoms may also be accompanied by sensory and motor dys-
functions, cognitive or other mental processing deficiencies, and other
neurological abnormalities. 10
The symptoms of the disorder essentially disassociate people with
autism from the world around them. For example, children with
autism may not want their mothers to hold them, and adults with
autism may not make eye contact with others. Some people afflicted
6. In 1943 Leo Kanner, a psychologist, published case histories of a childhood
development disorder he called autism. The modern concept of autism recognizes
Kanner's "classic autism" as autism, autistic disorder or AD, and includes this within a
broader category called autistic spectrum disorders or ASD. P.M. Kidd, Autism, An
Extreme Challenge to Integrative Medicine. Part 1: The Knowledge Base, 7 ALTERN. MED.
REV. 292, 293 (2002).
7. U.S. Dept. of Health and Human Services, National Institute of Child Health
and Human Development, NIH Pub. No. 01-4962, Autism Facts (June 2001),
8. Id.
9. Id.; see also Kidd, supra note 6, at 292 (describing three symptom patterns of
autism as "(1) the failure to use language for communication, (2) abnormal
development of social reciprocity, and (3) desire for sameness, as seen in repetitive
rituals or intense circumscribed interests").
10. Kidd, supra note 6, at 293.
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with autism never learn to speak, making the lives of those who care
for them very difficult."
Initial studies conducted in the 1960s indicated there were four to
five cases of autism in every 10,000 people, leading medical profes-
sionals and researchers to believe it was a rare condition. While the
exact prevalence of autism is not presently known, estimates range
from one in 500 cases to one in 1000 cases of autism diagnosed in the
United States every year. The dramatic increase in autism disorders
clearly shows that the condition is not rare. 12 In fact, some research-
ers suggest that autistic disorder (AD) and autistic spectrum disorder
(ASD) are epidemics.' 3 Statistics also demonstrate that boys are three
to four times more likely to be affected by autism than girls.' 4
While the exact cause of autism is unknown, there are several the-
ories regarding its etiology 15 that are being actively examined.' 6 For
instance, there is almost certainly a genetic susceptibility or predispo-
sition to autism.' 7 During the last 40 years, autism has also been
linked to many different potential causes, including various inborn
errors, genetic abnormalities including fragile X syndrome'", rubella
(caused by the rubella virus) and other pathogens, and many other
factors. Genetic predisposition, metabolic abnormalities, and abnor-
malities of the gastrointestinal, hepatic, and immune systems all
appear to be markedly involved.' 9 In addition, in recent years many
11. U.S. Dept. of Health and Human Services, supra note 7.
12. Id.
13. Kidd, supra note 6, at 295.
14. U.S. Dept. of Health and Human Services, supra note 7.
15. Kidd, supra note 6, at 298 (providing an overview of potential etiopathologic
factors in the development of autism).
16. U.S. Dept. of Health and Human Servicesalso Kidd, supra note 6, at 298
(providing an overview of potential etiopathologic factors in the development of
autism).
17. J.A. Lamb, J. Moore, A. Bailey, & A.P. Monaco, Autism: Recent Molecular Genetic
Advances, 9 HUM. MOL. GENET. 861, 861 (2000).
18. Fragile X Syndrome is a defect of the X chromosome which causes mild mental
retardation. The disorder occurs more frequently and severely among males than
females. The wide range of symptoms associated with the disorder include language
delays, behavioral problems, autism or autistic-like behavior (including poor eye
contact and hand-flapping), large or prominent ears, hyperactivity, delayed motor
development and/or poor sensory skills. U.S. Dept. of Health and Human Services,
National Institute of Child Health and Human Development, Families and Fragile X
Syndrome, at (last modified May 05, 2004).
19. Kidd, supra note 6, at 298-99 (providing an overview of potential
etiopathologic factors in the development of autism); see also M.T. Acosta & P.L. Pearl,
The Neurobiology of Autism: New Pieces of the Puzzle, 3 CURR. NEUROL. NEURISCI. REP.
149 (2003) (stating that while multiple etiologies of autism are implicated, genetic
2004]
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medical investigations have focused on the putative association
between certain childhood vaccines, namely the measles-mumps-
rubella (MMR) vaccine and vaccines containing the preservative thi-
merosal, and an increased risk of developing autism, autism spectrum
disorder, or other neurological abnormalities.
The potential association between certain childhood vaccinations,
particularly the MMR vaccine and thimerosal-containing vaccines, and
an increased risk of developing autism is highly controversial and cur-
rently disputed in the medical and scientific community. There have
been numerous studies conducted and review articles written to dis-
cern and clarify both the association between exposure to thimerosal
and an increased risk of developing autism2 ° and the association
between vaccination with the MMR vaccine and increased risk of devel-
oping autism.21 While the studies designed to address the potential
link between childhood vaccination with the MMR vaccine and autism
tend to refute such a link, the studies concerning thimerosal-contain-
ing vaccines do not definitively support or negate the existence of such
a causal association.
In 2000, at the request of the Centers for Disease Control and
Prevention (CDC) and the National Institutes of Health (NIH), the
Institute of Medicine (10M) at the National Academy of Sciences began
a review of the evidence linking MMR vaccine to autism.2 2 This inde-
pendent panel reviewed completed and ongoing studies, as well as
factors play a primary role); T. P. Berney, Autism-An Evolving Concept, 176 BR. J.
PSYCHIATRY 20, 22-23 (2000) (discussing genetic vulnerability in the etiology of
autism).
20. E.g., S. Bernard et al., The Role of Mercury in the Pathogenesis of Autism, 7 MOL.
PSYCHIATRY S42 (2002); M.F. Blaxill, L. Redwood, & S. Bernard, Thimerosal and
Autism? A Plausible Hypothesis That Should Not Be Dismissed, 62 MED. HYPOTHESES 788
(2004); Jj. Buescher, Vaccinations Containing Thimerosal Do Not Increase Rates of
Autism, 53 J. FAM. PRACT. 94 (2004); A. Hviid et al., Association Between Thimerosal-
Containing Vaccine and Autism, 290 JAMA 1963 (2003); J.R. Mann, Questions About
Thimerosal Remain, 9 Exp. BIOL. MED. (Maywood) 991 (2003). For further articles
examining the association between thimerosal and risk of autism, refer to Appendix 1.
21. E.g., W. Chen et al., No Evidence for Links Between Autism, MMR, and Measles
Virus, 34 PSYCHOL MED. 543 (2004); F. DeStefano, MMR Vaccine and Autism: A Review
of the Evidence for a Causal Association, 7 MOL. PSYCHIATRY S51 (2002); T. Jefferson et
al., Unintended Events Following Immunization with MMR: A Systematic Review, 21
VACCINE 3954 (2003); K.M. Madsen et al., A Population-Based Study of Measles, Mumps,
and Rubella Vaccination and Autism, 347 N. ENGL. J. MED. 1477 (2002); E. Purssell,
Exploring the Evidence Surrounding the Debate on MMR and Autism, 13 BR. J. NuRs. 834
(2004). For further articles exploring the association between MMR vaccination and
risk of autism, refer to Appendix 2.
22. U.S. Dept. of Health and Human Services, supra note 7.
[Vol. 27:91
4
Campbell Law Review, Vol. 27, Iss. 1 [2004], Art. 4
http://scholarship.law.campbell.edu/clr/vol27/iss1/4
CHILDHOOD VACCINATIONS
published medical and scientific papers, and heard testimony from
experts on vaccines and autism to determine whether there is a causal
link between autism and the MMR vaccine.23 The IOM concluded that
the evidence and testimony did not support an association between
autism and the MMR vaccine.24 In addition, The American Academy of
Pediatrics (AAP) held a conference on the MMR vaccine and autism in
which parents, scientists, and practitioners presented information on
this topic to a multi-disciplinary panel of experts. 25 The AAP similarly
concluded the available evidence does not support the notion that the
MMR vaccine causes or contributes to autism or other related
disorders. 26
However, the conclusions reached by the IOM and The AAP are
not universally accepted in the medical or scientific community. Some
researchers still contend that the MMR vaccine is causally related to
the increased prevalence of autism throughout the United States, par-
ticularly in California, a state which comprises 10 percent of the U.S.
population.27 Those who advocate a connection note that sharp
increases in autism prevalence in California and the United Kingdom
roughly parallel increases in the number of MMR vaccination adminis-
tered to children.28 Additionally, advocates note that the introduction
of the MMR vaccine in California is linked to an important change in
the pattern of onset of autism.29 According to the data collected since
1965 by the Autism Research Institute of California, prior to the early
1980s the majority of autism cases had onset at birth; however, since
that period far more cases of autism began to manifest around 18
months of age, which corresponds to the time after birth when most
children receive the MMR vaccine. 30 These contentions, however com-
pelling, generally are not accepted in the medical and scientific com-
munity. In fact, the majority of studies and review articles addressing
the putative association between the MMR vaccine and autism have
concluded there is no epidemiological data to support such an
association. 31
23. Id.
24. Id.
25. Id.
26. Id.
27. Kidd, supra note 6, at 308.
28. Id. at 307-08.
29. Id. at 308.
30. Id. (citing B. Rimland, The Autism Epidemic, Vaccinations, and Mercury, 10 J.
NUTR. ENVIRON. MED. 261 (2000)).
31. E.g., Chen et al., supra note 21; C.P. Farrington, E. Miller, & B. Taylor, MMR
and Autism: Further Evidence Against a Causal Association, 19 VACCINE 3632 (2001);
20041
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On the other hand, there is some support by medical profession-
als and the scientific community for the notion that exposure to thi-
merosal through vaccination is causally related to the development of
autism. Thimerosal is a preservative that has been added to certain
vaccines 32 since the 1930's due to its effectiveness in killing bacteria
and preventing bacterial contamination.33 When thimerosal is
degraded or metabolized inside the body, it produces ethyl mercury.34
Another type of mercury, methyl mercury, which is the most common
organic derivative of mercury, can accumulate in certain edible fresh-
water and saltwater fish.35 Methyl mercury can also accumulate in
humans who eat these fish.36 Exposure to high levels of methyl mer-
cury is toxic and can cause mental retardation, cerebral palsy, and
seizures. 37 The fetus is particularly sensitive to methyl mercury expo-
sure and may suffer brain damage or even death if exposed to high
levels. 38 However, not much is known about the effects of ethyl mer-
Madsen et al., supra note 21; B. Taylor et al., Autism and MMR Vaccination in North
London; No Causal Relationship, 7 MOL. PSYCHIATRY S7 (2002); B. Taylor et al., Autism
and Measles, Mumps, and Rubella Vaccine: No Epidemiological Evidence for a Causal
Association, 353 LANCET 2026 (1999). But see D.A. Geier & M.R. Geier, A Comparative
Evaluation of the Effects of MMR Immunization and Mercury Doses from Thimerosal-
Containing Childhood Vaccines on the Population Prevalence of Autism, 10 MED. SCI.
MONIT. 33 (2004) (concluding there is a biological plausibility and epidemiological
evidence showing a direct relationship between measles-containing vaccines and
serious neurological disorders); A.T. Phelan, MMR and Autism: An Overview of the
Debate to Date, 11 BR. J. NURs 621 (2002) (after reviewing two major studies, the
authors conclude that although epidemiological studies to date do not support a link
between MMR and autism, the studies have been too imprecise to rule out the
possibility that the MMR vaccine is involved in a small number of autism cases); K.
Wilson et al., Association of Autistic Spectrum Disorder and the Measles, Mumps,
Rubella Vaccine: A Systematic Review of Current Epidemiological Evidence, 157 ARCH.
PEDIATR. ADOLESC. MED. 628 (2003) (stating that while the current literature does not
suggest an association between ASD and the MMR vaccine, only limited
epidemiological evidence exists to rule out a link between a rare variant form of ASD
and the MMR vaccine). For further studies refuting an association between the MMR
vaccine and autism, refer to Appendix 3.
32. The vaccines currently under scrutiny for having contained thimerosal include
several variants of the Diphtheria-Tetanus-Pertussis (DTP), influenza, and hepatitis B
vaccines. In re Claims for Vaccine Injuries Resulting in Autism Spectrum Disorder v.
Sec'y of HHS, 2002 U.S. Claims LEXIS 365, at *1 (Fed. Cl. July 3, 2002).
33. U.S. Dept. of Health and Human Services, National Institute of Allergy and
Infectious Disease, NIAID Research on Thimerosal, at (last modified May 18, 2004).
34. Id.
35. Id.
36. Id.
37. Id.
38. Id.
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cury exposure in humans and how this compares to methyl mercury
exposure.39 In addition, there are important known differences
between methyl mercury exposure and thimerosal exposure.4 °
Namely, ethyl mercury is structurally different than methyl mercury
and the timing and route of exposure are different for the two chemi-
cals.4 1 More research is necessary to determine whether the guidelines
for methyl mercury exposure can be appropriately applied to thimero-
sal exposure.42
In July 1999, U.S. Department of Health and Human Services
agencies, The AAP, and vaccine manufacturers agreed that thimerosal
should be reduced or eliminated in vaccines as a precautionary mea-
sure and to reduce exposure to mercury from all sources.4 3 Today, all
routinely recommended pediatric vaccines currently manufactured for
the United States market are either free from thimerosal or contain
markedly reduced amounts of the substance.44 However, thimerosal is
still used in some vaccines that are administered to adults and adoles-
cents, as well as in some pediatric vaccines not appearing on the Rec-
ommended Childhood Immunization Schedule.
45
THE NATIONAL CHILDHOOD VACCINE INJURY ACT MANDATES A
UNIVERSAL PROCEDURE FOR THE LITIGATION OF VACCINE-RELATED
INJURY CLAIMS
The Vaccine Act46 established a National Vaccine Injury Compen-
sation Program ("Program") in 1986 in the U.S. Department of Health
and Human Services "to achieve optimal prevention of infectious dis-
eases through immunization and to achieve optimal prevention against
adverse reactions to vaccines."47 Congress enacted the Program for the
dual purposes of reducing tort litigation against vaccine manufacturers
and administrators, as well as to compensate individuals who may
39. Id.
40. U.S. Dept. of Health and Human Services, National Institute of Allergy and
Infectious Disease, NIAID-Supported Studies on Mercury, Thimerosal, and Vaccine
Safety, at (last modified May 20, 2004).
41. Id.
42. U.S. Dept. of Health and Human Services, supra note 33.
43. Id.
44. Id.
45. Id.
46. National Childhood Vaccine Injury Act, 42 U.S.C. §§ 300aa-1-34 (2000).
47. Id. § 300aa-1.
2004]
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have been harmed by vaccinations.4" In order to achieve this end, the
Program mandates that:
[n]o person may bring a civil action for damages in an amount greater
than $1,000 or in an unspecified amount against a vaccine administra-
tor or manufacturer in a State or Federal court for damages arising
from a vaccine-related injury or death associated with the administra-
tion of a vaccine . . . and no such court may award damages in an
amount greater than $1,000 in a civil action for damages for such a
vaccine-related injury or death, unless a petition has been filed, in
accordance with [42 USCS § 300aa-16], for compensation under the
Program for such injury or death ....
Congress designed the Program as an alternative to tort litigation
against vaccine manufacturers and administrators, intending that each
Program petitioner be able to obtain an evaluation of his or her claim
of vaccine-related injury.5" While Congress certainly hoped that a
claimant receiving a Program award as a result of such an evaluation
would accept the award and forego the option of a tort suit, Congress
also hoped that many claimants who were denied Program awards
would nevertheless be satisfied with their day in court. As such, Con-
gress did not make the Program the exclusive remedy for vaccine-
related injuries.5 '
Congress instead designed the Program to give any claimant who
was dissatisfied with the size of a Program award or who failed to
obtain a Program award the option of rejecting the Program verdict
and pursuing a civil action against the vaccine manufacturer or admin-
istrator.52 Specifically, in order for a petitioner to directly sue a vac-
48. Stewart v. Sec'y of HHS, 2002 U.S. Claims LEXIS 363, at *21 (Fed. Cl. Dec. 30,
2002). See also Schafer v. Am. Cyanamid Co., 20 F.3d 1, 4, 1994 U.S App. LEXIS 5477(1st Cir. 1994) (stating that "an important federal purpose of the [Vaccine] Act is to
free manufacturers from the specter of large, uncertain tort liability, and thereby keep
vaccine prices fairly low and keep manufacturers in the market" and that "[t]he Act
seeks to achieve its cost-reducing purpose, not by denying compensation to
victims . .. , but by reducing the litigation and insurance costs related to lengthy,
complex tort procedures and random large tort awards" ); McDonald v. Lederle Labs.,
775 A.2d 528, 530 (NJ. Super Ct. App. Div. 2001), affd in part and rev'd in part on
other grounds, 841 A.2d 948 (NJ. Super. Ct. App. 2004). (the Program was established
"to protect the vaccine supply from market instability created by an increasing number
of vaccine-related personal injury lawsuits").
49. 42 U.S.C. § 300aa-11(a)(2)(A).
50. Stewart, 2003 U.S. Claims LEXIS 275, at *43.
51. Stewart, 2003 U.S. Claims LEXIS 275, at *43; see also 42 U.S.C. §§ 300aa-
11(a), 300aa-21(a).
52. Stewart, 2003 U.S. Claims LEXIS 275, at *43-44; see also 42 U.S.C. §§ 300aa-
11(a), 300aa-21(a).
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cine manufacturer or administrator for a vaccine-related injury one of
two things must occur at the conclusion of a proceeding with respect
to a petition filed under the Program: (1) the Court of Federal Claims
must have issued a judgment on such petition, and the petitioner must
have filed an election declining to accept that judgment and choosing
instead to proceed with a suit against the vaccine manufacturer or
administrator or (2) the petitioner must have elected to withdraw the
Program petition under section 300aa-21(b) of the Vaccine Act.53 The
filing of a petition under the Program for a vaccine-related injury or
death stays the running of the statute of limitation with respect to a
civil action brought for such injury or death beginning on the date the
petition is filed and ending on the date the petitioner either files an
election declining to accept the judgment rendered by the Federal
Claims Court or elects to withdraw the petition.54
There are two different means of establishing entitlement to com-
pensation under the Program.55 First, if an injury specified in the Vac-
cine Injury Table, occurred within the time period after vaccination
56
prescribed in that Table, then the injury is presumed to qualify for
compensation.57 If a person qualifies under this presumption, he is
said to have suffered a Table Injury.58 Alternatively, compensation
may be awarded for injuries not listed in the Table; however, entitle-
ment in such cases is dependent upon proof that the vaccine actually
caused the injury. 59 Although Congress correctly anticipated that
most petitions would involve Table Injury claims when it published the
initial Vaccine Injury Table, in recent years, most Program cases,
53. Stewart, 2003 U.S. Claims LEXIS 275, at *15-16; see 42 U.S.C. §§ 300aa-
11(a)(2)(A)(i)-(ii); see also Ashton v. Aventis Pasteur, Inc., 2004 PA Super. 202, 1 7,
851 A.2d 908 (stating that "[t]he language of the Act relative to wherein jurisdiction
lies is clear: a claimant's exhaustion of the Act's statutory remedy is a condition
precedent to subject matter jurisdiction of a state or federal court to resolve the merits
of a claim filed by an individual seeking damages for a vaccine-related injury").
54. See 42 U.S.C. § 300aa-16(c).
55. Stewart, 2003 U.S. Claims LEXIS 275, at *46.
56. The vaccines included in the Vaccine Injury Table include (1) DTP, P, DTP/
Polio combination, or any other vaccine containing whole cell pertussis bacteria,
extracted or partial cell bacteria, or specific pertussis antigen(s), (2) measles, mumps,
rubella, or any vaccine containing any of the foregoing component, DT, Td, or tetanus
toxoid, (3) polio vaccines, and (4) inactivated polio vaccine. 42 U.S.C. § 300aa-14(a).
57. Stewart, 2003 U.S. Claims LEXIS 275, at *46; see 42 U.S.C. §§ 300aa-
13(a)(1)(A), 300aa-11(c)(1)(C)(I), 300aa-14(a).
58. Stewart, 2003 U.S. Claims LEXIS 275, at *46.
59. Stewart, 2003 U.S. Claims LEXIS 275, at *46; see 42 U.S.C. §§ 300aa-13(a)(1),
300aa-1 l(c)(1)(C)(ii).
20041
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including autism 60 cases, have involved non-Table claims of actual
causation.6 '
First, to maintain an action against the government for Program
compensation, individuals must demonstrate that their claim meets
the filing prerequisites of the Vaccine Act. 62 Section 11(a) of the Vac-
cine Act is the gate-keeping provision of the statute which sets forth
the general rules describing when a vaccinee may petition for compen-
sation. 61 Sections 300aa-1 I(c)(1)(A)-(E) of the Vaccine Act are the spe-
cific provisions describing qualified Vaccine Court litigants.64
THE STATUTE OF LIMITATIONS OF THE NATIONAL CHILDHOOD VACCINE
INJURY ACT AND EQUITABLE TOLLING
Individuals seeking relief under the Vaccine Act must also act
within the prescribed statute of limitations. Section 300aa-16(a)(2)
dictates that in the case of
a vaccine set forth in the Vaccine Injury Table which is administered
after the effective date of this part, if a vaccine-related injury occurred
as a result of the administration of such vaccine, no petition may be
filed for compensation under the Program for such injury after the
expiration of 36 months after the date of the occurrence of the first
symptom or manifestation of onset or of the significant aggravation of
such injury .... 65 (emphasis added)
Congress is currently scrutinizing the statute of limitations for
claims under the Vaccine Act and a strong possibility exists that the
limitations period may be extended to six years.66 However, under the
current statutory scheme, a qualified petitioner under the Vaccine Act
60. Autism does not appear in the Vaccine Injury Table as an "[ililness, disability,
injury, or condition covered" for the purpose of receiving compensation under the
Program. 42 U.S.C. § 300aa-14(a).
61. Stewart, 2003 U.S. Claims LEXIS 275, at *46.
62. Leroy v. Sec'y of HHS, 2002 U.S. Claims LEXIS 284, at *9 (Fed. Cl. Oct. 11,
2002).
63. Id; see Amendola v. Sec'y of HHS, 989 F.2d 1180, 1182-83 (Fed. Cir. 1993); see
also Klahn v. Sec'y of HHS, 31 Fed. Cl. 382, 385 (1994) ("The court's jurisdiction
involves compliance with [these] gate-keeping provisions . . .").
64. Cheskiewicz, 2004 PA Super 40, c 12, 843 A.2d at 1263. The requirements are
that a petitioner: (1) received a vaccine set forth in the Vaccine Injury Table, (2) in the
United States, (3) sustained an injury caused by the vaccine, (4) suffered residual
effects for more than six months after the date of vaccination, died as a result of
administration of the vaccine, or suffered illness or injury from the vaccine which
resulted in inpatient hospitalization, and (5) has not previously received
compensation. 42 U.S.C. §§ 300aa-11(c)(1)(A)-(E).
65. 42 U.S.C. § 300aa-16(a)(2).
66. Setnes v. United States, 57 Fed. Cl. 175, 178 (2003).
100 [Vol. 27:91
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must not only satisfy those prerequisites listed in § 300aa-11(c)(1),
but also file a claim with the Vaccine Court within three years from
either the date of (1) the occurrence of the first symptom or (2) the
manifestation of onset of injury experienced as a result of vaccination.
Either event triggers the running of the statute of limitations and
courts should apply the standard appropriate for the facts of each
case.
67
Because autism is a disorder with no dramatic or obvious onset,
determining the first symptom of an autistic disorder is a question of
fact that is quite complex in many cases.68 Many of the initial symp-
toms of autism are subtle and can be easily confused with typical
childhood behavior. 69 Therefore, in Vaccine Act claims based on
autism or other conditions where there is no clear start to the injury, a
court addressing the statute of limitations should not hinge its deci-
sion on the occurrence of the first symptom standard.7 ° Instead,
where the symptoms of autism develop insidiously over time and the
child's behavior cannot be readily associated with an injury or condi-
tion, the court should rely on the child's medical or psychological eval-
uations for guidance in ascertaining when the manifestation of onset
occurred. 7'
Although the standard of determining the first symptom of or
manifestation of onset of autism appears to favor petitioners under the
Program, the court's stance on equitable tolling72 is less forgiving. The
court in Weddel v. Secretary of Health and Human Services, held that
equitable tolling of the limitations period is not available for claims
arising under section 16(a)(1) of the Vaccine Act, which applies to vac-
cines administered prior to the effective date of the Act ("pre-Act
cases").73 Along the same lines, in Brice v. Secretary of Health and
67. Id. at 179.
68. Stewart, 2002 U.S. Claims LEXIS 363, at *9; see also Setnes, 57 Fed. Cl. at 179.
69. Setnes, 57 Fed. Cl. at 179.
70. Id.
71. Id. at 181 (rev'd Setnes v. Sec'y of HHS, 2003 U.S. Claims LEXIS 30 (Fed. Cl.
Jan. 31, 2003), which held that the Vaccine Act does not require that a symptom be
diagnosed in order for the statute of limitations to start to run in causation in fact
cases); see also Kuehn v. Sec'y of HSS, 2003 U.S. Claims LEXIS 286, at *13 (Fed. Cl.
July 23, 2003) (applying the holding in Setnes v. United States in declaring that a
medical diagnosis of autism is a clear indication of the time of onset of a child's
autism).
72. If equitable tolling were to be allowed, the running of the statute of limitations
would be delayed until a petitioner actually discovers that the vaccine caused the
injury. Vessels v. Sec'y of HSS, 2002 U.S. Claims LEXIS 286, at *8 (Fed. Cl. Sept. 25,
2002).
73. 100 F.3d 929 (Fed. Cir. 1996).
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Human Services,"4 the court held that equitable tolling is also not avail-
able for claims arising under section 16(a)(2) of the Vaccine Act,
which applies to vaccines administered after the effective date of the
Vaccine Act ("post-Act cases"). 75
In Brice, this determination was based on two decisive factors.7 6
First, the Vaccine Act includes a specific exception to the limitations
period for a petition improperly filed in state or federal court. 77 Spe-
cifically, such a petition must be dismissed from the court in which it
was improperly filed, but the date such dismissed action was filed is,
for the purposes of the limitations of actions, considered to be the date
the petition was filed if the petition was filed within one year of the
date of the dismissal of the civil action.78 When an Act includes spe-
cific exceptions to a limitations period, the court is "not inclined to
create other exceptions not specified by Congress. ' 79 Second, the leg-
islative history of the Vaccine Act emphasizes the importance of quick
resolution of claims.80 The limitations period is part of a detailed stat-
utory scheme that includes other strict deadlines.' For example, the
special masters who preside over Vaccine Act claims are required to
issue decisions within 240 days of the filing of the petition 2 and may
suspend proceedings for no more than a total of 150 days.8 3 Accord-
ing to the court in Brice, to allow equitable tolling would conflict with
the principle of quick claim resolution fostered by the Vaccine Act
because it "invites prolonged and wasteful collateral litigation concern-
ing the running of the statute of limitations. '8 4
In upholding the Brice decision, the court in Lemire v. Secretary of
Health and Human Services held that "the Federal Circuit in Brice did
not distinguish between Table and off-Table cases in holding that equi-
table tolling is inapplicable in Vaccine Act cases."81 5 This case involved
a non-Table causation in fact claim where petitioner asserted that,
because a causation in fact case has the traditional tort burden and is a
lengthier proceeding than a Table case, an off-Table case cannot be
74. 240 F.3d 1367 (2001).
75. Id.
76. Id. at 1373.
77. Id.
78. Id; see 42 U.S.C. § 300aa-11(a)(2)(B) (2000).
79. Brice, 240 F.3d at 1373.
80. Id.
81. Id.
82. See 42 U.S.C. § 300aa-12(d)(3)(A)(ii).
83. See 42 U.S.C. § 300aa-12(d)(3)(C).
84. Brice, 240 F.3d at 1373.
85. 2002 U.S.Claims LEXIS 285 (Fed. C1. Sept. 25, 2004).
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speedy and equitable tolling should apply.8 6 However, the court rea-
soned that "applying equitable tolling to causation in fact cases would
lengthen their resolution even further in direct opposition to congres-
sional intent.
8 7
Another issue arising as a result of the Vaccine Act's statute of
limitations period is whether a subsequent civil action is barred by the
Act where a judgment of dismissal is entered by the United States Fed-
eral Claims Court due to the petitioner's failure to file a claim petition
within the 36 month period. 8 The Federal Claims Court has deter-
mined that a petitioner's failure to prosecute and file a timely petition
under the Vaccine Act precludes such petitioner from pursuing a sub-
sequent state tort action on behalf of a child suffering a vaccine-related
injury.8 9 In making this determination, the court states that the Act
"expressly warns that a victim's traditional tort claim will not be saved
by a state statute of limitations that extends beyond the limitations
period proscribed by the Act, if a claim is not filed with the Program
within its time restrictions. "90
DEVELOPMENT AND IMPORT OF THE OMNIBUS AUTISM PROCEEDING
In 2002 the Office of Special Masters ("OSM") issued the Autism
General Order #1 ("Order") to address the growing concern in recent
years that certain childhood vaccinations might be causally related to
the apparent increase in the diagnosis of autism spectrum disorder. 9'
Specifically, it has been alleged that autism or other similar
neurodevelopmental disorders may be caused by MMR vaccinations;
by the thimerosal ingredient contained in certain Diphtheria-Tetanus-
Pertussis (DTP), Diphtheria-Tetanus-acellar Pertussis (DTaP), Hepatitis
B, and Hemophilus Influenza Type B (HIB) vaccinations; or some com-
bination of the two.92 At the time of publication of the Order, over 400
cases alleging a causal relationship between these vaccinations and
autism disorders had been filed in the Vaccine Court.93 Additionally,
numerous civil lawsuits against vaccine manufacturers were filed
around the country, alleging Thimerosal caused autism.94 A recent
86. Id. at *14-15.
87. Id. at *15.
88. McDonald, 775 A.2d at 529.
89. Id.
90. Id. at 534.
91. In re Claims for Vaccine Injuries, 2002 U.S. Claims LEXIS 365, at *1.
92. Id.
93. Id. at *2.
94. Id.
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ruling determined as a matter of law that such claims against vaccine
manufacturers must be dismissed and brought as Program claims. 95
As a result of the influx of Program claims and the potential for many
more such claims, the OSM, through a series of meetings and discus-
sions with an informal advisory committee, developed a procedure to
resolve these case within a reasonable time frame. The advisory com-
mittee included petitioners' counsel representing many current and
potential Program claimants and legal and medical representatives of
the Secretary of Health and Human Services. 96 The OSM adopted a
two-step procedure. First, the OSM will inquire into the general causa-
tion issues involved in these cases (i.e., whether the vaccinations in
question can cause autism and/or similar disorders, and if so under
what circumstances); and second, the conclusions reached in that gen-
eral inquiry will be applied to the cases of the individual claimants. 97
This general inquiry (called the "Omnibus Autism Proceeding") 98 will,
after a period of discovery, a designation of experts for each side, and
an evidentiary hearing, ultimately result in a special master's ruling on
the general causation issues. Then, these conclusions regarding causa-
tion issues will be applied to individual cases.99 The OSM did man-
date that its "decision on the causation issues shall be rendered within
two years after the filing of this General Order." ' Although it is pres-
ently more than two years after the filing of the Order, the OSM has yet
to rule on the causation issues. Therefore, all petitioners who seek
relief under the Program must wait until such a ruling is made before
the option of a civil suit becomes available.
The most recent update to the Autism Master File was filed on
October 28, 2004. On this date, more than 4,400 petitions in autism
cases had been filed, and more than 4,250 remain pending, stayed
until the conclusion of the Omnibus Autism Proceeding. Additional
petitions continue to be filed regularly.'0° There is no indication from
the most recent update to the Autism Master File that a decision on the
95. Id. at *1 (citing Owens v. American Home Products Corp., 203 F. Supp. 2d
748 (S.D. Tex. 2002)).
96. Id. at *3-4.
97. Id. at *7.
98. The documents filed in the Omnibus Autism Proceeding are contained in a
special file known as the "Master Autism File," which can viewed on the United States
Court of Federal Claims website at
99. In re Claims for Vaccine Injuries, 2002 U.S. Claims LEXIS 365, at *7-8.
100. Id. at *4.
101. In re Claims for Vaccine Injuries Resulting in Autism Spectrum Disorder,
Office of Special Masters, Autism Master File, Autism Update, at (October 28, 2004).
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general causation issues will be forthcoming anytime in the near
future. 1°2
THE CONSTITUTIONALITY OF THE NATIONAL CHILDHOOD VACCINE INJURY
ACT WITH REGARD TO AUTISM AS A VACCINE-RELATED INJURY
REMAINS UNDETERMINED
In addition to the regulations and standards prescribed by the
Vaccine Act described above, section 1 l(a)(6) imposes a further road-
block to receiving compensation for a vaccine-related injury under the
Program. This section provides that "[i]f a person brings a civil action
after November 15, 1988 for damages for a vaccine-related injury or
death associated with the administration of a vaccine before November
15, 1988, such person may not file a petition under [the Vaccine Act]
for such injury or death." 10 3 The effect of this provision is to bar the
filing of a Vaccine Act petition for compensation if a civil action for
damages was filed after November 15, 1988, if the vaccine-related
injury allegedly associated with a vaccination occurred before this
date.'0t Although this provision has little effect on parents of autistic
children seeking redress for such vaccine-related injury today (because
the statute of limitations of the Vaccine Act would bar such a claim),
past petitioners have argued that this statutory provision violates the
equal protection clause of the Constitution.
105In Greider v. Secretary of Health and Human Services, the peti-
tioner filed a civil action in state court against the administrator and
manufacturer of a polio vaccine several months before filing a vaccine
petition.'0 6 On April 5, 1991, the Special Master issued an order dis-
missing the claimant's petition as in violation of section 1 1(a)(6) of the
Vaccine Act. In response, petitioner argued that the Special Master's
interpretation of section 11(a)(6) violated the equal protection clause
of the Constitution because the Act treats similarly situated persons
differently and constitutes "arbitrary and irrational discrimination."107
In response, the court first noted that, while Congress did establish
different rules based upon the date of the vaccine-related injury, it was
"not at liberty to change a statute enacted by Congress" and that
because "the language of the statute is crystal clear and is supported
102. Id.
103. 42 U.S.C. § 300aa-11(a)(6) (2000).
104. Greider v. Sec'y of HHS, 23 Cl. Ct. 348, 349 (1991).
105. Id. at 349.
106. Id.
107. Id. at 350.
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by the legislative history, the court must defer to its clear meaning."' 0
Second, the court also held that it had no jurisdiction to hear claims
grounded in the due process or equal protection guarantees of the Fifth
Amendment of the Constitution because these provisions do not obli-
gate the federal government to pay money damages.'0 9 Third, the
court stated that petitioner's argument lacked a rational basis because
those persons with pre-Act injuries who filed a civil action before
November 15, 1988 had no option to pursue a remedy under the Vac-
cine Act at the time they filed their civil actions. However, those per-
sons with pre-Act injuries who filed a civil action after November 15,
1988 clearly had a choice of forum. 1" Therefore, the two different
groups of claimants, according to the court, are not similarly situated
and petitioner's equal protection argument is unavailing.' 1 '
Since Greider, other petitioners have asserted that the prevailing
interpretation of limitations of actions under the Vaccine Act render its
provisions unconstitutional. In Kuehn v. Secretary of Health and
Human Services, petitioners, who are the parents of a boy allegedly
injured by a series of thimerosal-containing vaccines, argue that the
Vaccine Act's statute of limitations, namely section 300aa-16(a)(2),
violate their equal protection rights "due to the insidious nature of the
onset of autism compared to the more clear and dramatic onset of
other vaccine related injuries."' 1 2 However, the court did not reach the
substance of this argument because the Vaccine Act, which is the
source of the special masters' authority, does not give the special
master the power to address the constitutionality of the Act's
provisions. 113
In Cheskiewicz v. Aventis Pasteur, Inc., the parents of an autistic
boy who was diagnosed with disintegrative autism resulting from mer-
cury toxicity seven years after he was administered his first vaccine" 14
claimed on appeal that "an interpretation of the Act barring [their]
claim from proceeding in state court renders its provisions unconstitu-
tional in violation of equal protection, due process, and their right to a
jury trial."' 15 The petitioners initially brought an action to recover for
their son's vaccine-related injuries in the Philadelphia Court of Com-
108. Id.
109. Id; see Carruth v. United States, 224 Ct. Cl. 422, 445, 627 F.2d 1068, 1081
(1980).
110. Greider, 23 CI. Ct. at 350-51.
111. Id. at 351.
112. 2003 U.S. Claims LEXIS 286, at *3.
113. Id. at *8-9.
114. 2004 PA Super 40, J 3, 843 A.2d at 1261.
115. Id. at 8, 843 A.2d at 1262.
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mon Pleas in May 2002.116 They filed the petition approximately six
and one-half years after the first manifestation of his symptoms and
three and one-half years after the expiration of the Vaccine Act statute
of limitations. 117 The trial court dismissed the petitioners' claim pur-
suant to the Vaccine Act's requirement that claimants "first exhaust the
remedies provided by the Act""' 8 and rejected petitioners' claims that
the Act's statute of limitations was unconstitutional "as lacking sup-
porting authority." 119 On appeal, as in Kuehn, the court did not
address the constitutionality of the Vaccine Act's provisions, but held
that because "[p]arents do not have a right to bring an action in state
court until they have exhausted their administrative remedies," 121 the
Vaccine Court "is the appropriate forum in which to raise the constitu-
tional issues.'' In this regard, it must be noted that "the Vaccine Act
does not provide any textual authority to the special masters to deter-
mine the [c]onstitutionality of its provisions"' 22 and because the Act is
the source of the special masters' authority, the Vaccine Court may not
"entertain claims outside its statutorily created jurisdictional author-
ity.' 2 3 However, under section 300aa-12(f), the Vaccine Act allows for
appeal from the United States Federal Claims Court (the Vaccine
Court) to the Federal Circuit,' 24 "where a constitutional challenge can
be entertained.' 1 25 Therefore, petitioners not only must file a claim in
the Vaccine Court when they know such claim will be unavailing
because of the statute of limitations, but must also appeal the denial of
this claim for the constitutionality of the Act's provisions to be prop-
erly addressed by the court. No claims challenging the constitutional-
ity of the Act's limitation on civil actions have been adjudicated in the
Federal Circuit on appeal from rulings of the Federal Claims Court.
The decisions of the Federal Claims Court, such as in Kuehn and Ches-
kiewicz, do not indicate whether constitutional challenges to the Vac-
cine Act would prevail on appeal to the Federal Circuit. However, the
116. Id. at 9 4, 843 A.2d at 1261.
117. Id.
118. Id. at 9 6, 843 A.2d at 1261.
119. Id.
120. Id. at 18, 843 A.2d at 1264; see Ashton, 2004 PA Super 202, 9 11 (holding
that because "Parents do not have a right to bring an action in state court until they
have exhausted their administrative remedies .. ., it would be judicially imprudent
... to discuss the constitutionality of the Vaccine Act").
121. Cheskiewicz, 2004 PA Super 40, '1 18, 843 A.2d at 1264.
122. Kuehn, 2003 U.S. Claims LEXIS 286, at *9.
123. Id. at *8.
124. 42 U.S.C. § 300aa-12(f) (2000).
125. Cheskiewicz, 2004 PA Super 40, 9 18, 843 A.2d at 1264.
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fact that a strong possibility exists that the statute of limitations of the
Vaccine Act may be extended to six years 126 is indicative of Congress'
awareness that the Act's limitation on actions treats children who alleg-
edly developed autism as a result of vaccinations unfairly due to the
insidious nature of the onset of autism in comparison to the more
immediate onset of other vaccine-related injuries.
CONCLUSION
The prevalence of autism has increased dramatically in recent
years, causing well-founded concern among many parents and pro-
spective parents. Some researchers even suggest that autism has
become epidemic. 127 While the exact cause of autism is unknown,
many factors are implicated in its etiology, including exposure to cer-
tain childhood vaccinations, particularly those containing the preser-
vative thimerosal. The National Vaccine Injury Compensation
Program, established under the Vaccine Act, functions both "to achieve
optimal prevention of infectious disease" through the use of immuniza-
tion and "to achieve optimal prevention against adverse reactions to
vaccines.'128 Parents of children who allegedly developed autism as a
result of childhood vaccination must, under the Program, seek redress
first with the Federal Claims Court within the prescribed statute of
limitations and have no right to maintain a traditional civil tort suit
against the vaccine manufacturer. For most petitioners under the Pro-
gram, this limitation does not negate their ability to be adequately
redressed for their children's vaccine-related injuries. However, due to
the insidious nature of the onset of autism, the resulting difficulty and
delay in its diagnosis, and the fact that only recently has a putative
association between thimerosal and autism been recognized, parents
of children with autism are placed at a distinct disadvantage under the
current statutory scheme of the Vaccine Act. Additionally, because the
special masters of the Federal Claims Court are not conferred with the
authority to address constitutional challenges to the Vaccine Act, the
issue of whether the limitations of actions provisions in the Vaccine
Act are unconstitutional, particularly with regard to equal protection
violations, has not been determined. The OSM, through the Omnibus
Autism Proceeding, will hopefully render a determination on the issue
of thimerosal's causal connection to the development of autism so that
126. Setnes, 57 Fed. Cl. at 178.
127. Kidd, supra note 6, at 295 (providing an overview of potential etiopathologic
factors in the development of autism).
128. 42 U.S.C. § 300aa-1.
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the thousands of petitioners with claims pending in the Federal Claims
Court can either receive the appropriate compensation or, in the event
that an adverse ruling results, be able to pursue a civil tort remedy.
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